Signios Biosciences ("Signios Bio"), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced the winners of the ...
Endurance sport lover Lucy Gillis was 16 weeks’ pregnant when she became paralysed from the neck down. It was 2023, and ...
Lucy Wales was a fit mother midway through her second pregnancy — but her life suddenly took a horror turn when she was left ...
A new study published in Scientific Reports indicates that amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have an extremely high geographic association, even after controlling for ...
Multiple sclerosis (MS) is an autoimmune condition in which the protective insulation surrounding neurons in the brain and spinal cord is erroneously attacked. This can cause a wide variety of serious ...
Get the latest federal technology news delivered to your inbox. Several divisions in the Cybersecurity and Infrastructure Security Agency were affected in termination orders issued to the federal ...
Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...
HENRICO COUNTY, Va. — Walking into Mimi Murdock's Henrico home is a lot like stepping into a painting. "My house, everything's fluid, you know, it's just going to change," Murdock said. "I'm a visual ...
She was diagnosed with multiple sclerosis in 2018. Selma Blair, 53, is giving fans an update on her battle with the autoimmune disease. Speaking on “Today” on NBC, the “Cruel Intentions” actress from ...
eMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, ...
EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results